Inqovi
Payments companies reported to CMS as associated with Inqovi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Inqovi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Inqovi
These are the largest totals companies reported as associated with Inqovi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Salman Fazal | Pittsburgh, PA | Hematology & Oncology | $87,522.52 |
| Jason Salganick | Phoenix, AZ | Medical Oncology | $53,855.69 |
| Bart Scott | Seattle, WA | Medical Oncology | $49,586.63 |
| Amer Zeidan | New Haven, CT | Hematology & Oncology | $46,955.00 |
| Leland Metheny | Cleveland, OH | Hematology (Internal Medicine) | $16,645.96 |
| Michael Levitt | Manasquan, NJ | Hematology & Oncology | $11,884.30 |
| Alexis Cruz Chacon | San Juan, PR | Hematology & Oncology | $8,423.08 |
| Ruemu Birhiray | Indianapolis, IN | Hematology & Oncology | $6,877.56 |
| Harry Erba | Ann Arbor, MI | Medical Oncology | $6,471.79 |
| Guillermo Garcia-Manero | Houston, TX | Medical Oncology | $5,725.32 |
Prescribed Inqovi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.